RT Journal Article
SR Electronic
T1 Adjuvant Radiotherapy in Patients With Pancreatic Adenocarcinoma. Is It Still Appealing in Clinical Trials? A Meta-analysis and Review of the Literature
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4697
OP 4704
DO 10.21873/anticanres.15283
VO 41
IS 10
A1 FRANCESCO PASQUALETTI
A1 ALDO SAINATO
A1 RICCARDO MORGANTI
A1 CONCETTA LALISCIA
A1 ENRICO VASILE
A1 ALESSANDRA GONNELLI
A1 SABRINA MONTRONE
A1 GIOVANNI GADDUCCI
A1 NOEMI GIANNINI
A1 NATALINA COCCIA
A1 TAIUSHA FUENTES
A1 SOFIA ZANOTTI
A1 MASSIMO FALCONI
A1 FABIOLA PAIAR
YR 2021
UL http://ar.iiarjournals.org/content/41/10/4697.abstract
AB Aim. Pancreatic adenocarcinoma is a life-threatening disease with a rising frequency and the fourth leading cause of cancer death. This review aimed to assess the impact of postoperative radiotherapy through a meta-analysis of prospective randomized studies. Materials and Methods: Six studies met the inclusion criteria and were analyzed to calculate the cumulative risk of death (hazard ratio) in patients affected by pancreatic cancer treated with or without radiotherapy. Higgins’ index was used to determine heterogeneity in between-study variability and, subsequently, the random-effects model was applied according to DerSimonian and Laird. Results: Eight hundred and thirty-seven patients were analyzed (418 in the control arm and 419 in the treatment one), the hazard ratio for death after randomization was 0.92 (p=0.560, 95% confidence interval=0.70-1.22). When scrutinizing these studies, only one out of six showed a statistically significant benefit due to the addition of radiotherapy in the postoperative setting. Conclusion: We conclude that the use of adjuvant radiotherapy is not beneficial in treating all patients affected by pancreatic cancer but only for a subset of cases with potential residual local disease.